Antiviral Drug Resistance: Mechanisms and Clinical Implications

Strasfeld, Lynne; Chou, Sunwen

doi:10.1016/j.idc.2010.01.001

Cited by 180 publications

(135 citation statements)

References 197 publications

(205 reference statements)

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…This resistance is developed both in vitro and in vivo, and it is very significant in immunocompromised patients. 10,40 Therefore, new, potent, and selective antiviral agents are necessary to provide alternative HSV-1 treatment choices, with (29) and (30) representing attractive candidates for development as new antivirals. The structural relatedness of (29) and (30) suggests that such structure scaffolds may be of interest for further synthesis and SAR investigations.…”

Section: Resultsmentioning

confidence: 99%

A Strategy for the Rapid Identification of Fungal Metabolites and the Discovery of the Antiviral Activity of Pyrenocine a and Harzianopyridone

Ióca¹,

Romminger²,

Santos³

et al. 2016

Química Nova

View full text Add to dashboard Cite

The isolation and identification of bioactive metabolites from complex extracts obtained from microbial growth media is a time consuming, costly, and labor-intensive task. A strategy to rapidly identify secondary metabolites isolated from extracts obtained from the culture media of marine-derived and endophytic fungal strains is described. Identification was achieved by HPLC-UV-MS and 1 H NMR analyses in combination with data obtained from the Dictionary of Natural Products. Among the compounds identified, (-)-naphthoquinoneimine, citreorosein, emodin, pyrenocine A and harzianopyridone displayed moderate to potent antiviral activity. (-)-Naphthoquinoneimine was isolated as the enantiomer of its previously reported dextrorotatory congener, while 6,7-dihydroxy-2,2-dimethyl-4-chromanone is herein reported for the first time as a natural product.

show abstract

“…Current chemotherapeutic antiviral drugs have been characterized as having in many cases limited clinical efficacy, resistance and toxic side effects (Strasfeld and Chou, 2010). Therefore, it is necessary to identify and develop Fig.…”

Section: Discussionmentioning

confidence: 99%

Development of real-time RT-PCR for human metapneumovirus

Xue¹,

Zheng²,

Zhang³

2011

View full text Add to dashboard Cite

Summary. -Literature pertaining to the interactions between Marek΄s disease virus (MDV) entry-related glycoproteins and corresponding receptors is still limited. Results from a Western blot analysis of cellular proteins for virus receptors and co-immunoprecipitation suggest that heat shock protein 70 (HSP70) is a potential cellular receptor for MDV glycoprotein gH. Plaque inhibition assays confirm the involvement of HSP70 in the early stages of MDV entry into chicken embryo fibroblasts (CEF). The present work supports that HSP70 is implicated in the MDV entry process by binding to gH, and enhances the understanding of multifunctional HSP70 and the MDV infection process.

show abstract

“…Despite the existence of resistance mechanisms that are specific to some classes of microbes/drugs, resistance mechanisms that are common among all microbes and many chemotherapeutic agents exist (Borst and Ouellette, 1995; Viveiros et al, 2005; Kanafani and Perfect, 2008; Strasfeld and Sunwen, 2010; Akhdar et al, 2012; Li et al, 2016). …”

Section: Introductionmentioning

confidence: 99%

The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy

El‐Awady

Saleh²,

Hashim

et al. 2017

Front. Pharmacol.

View full text Add to dashboard Cite

Over the years chemotherapy failure has been a vital research topic as researchers have been striving to discover reasons behind it. The extensive studies carried out on chemotherapeutic agents confirm that resistance to chemotherapy is a major reason for treatment failure. “Resistance to chemotherapy,” however, is a comprehensive phrase that refers to a variety of different mechanisms in which ATP-binding cassette (ABC) mediated efflux dominates. The ABC is one of the largest gene superfamily of transporters among both eukaryotes and prokaryotes; it represents a variety of genes that code for proteins, which perform countless functions, including drug efflux – a natural process that protects cells from foreign chemicals. Up to date, chemotherapy failure due to ABC drug efflux is an active research topic that continuously provides further evidence on multiple drug resistance (MDR), aiding scientists in tackling and overcoming this issue. This review focuses on drug resistance by ABC efflux transporters in human, viral, parasitic, fungal and bacterial cells and highlights the importance of the MDR permeability glycoprotein being the mutual ABC transporter among all studied organisms. Current developments and future directions to overcome this problem are also discussed.

show abstract

“…The emergence of drug-resistant mutants has received the world's attention to develop new antivirals with better drug resistance and pharmacokinetic profiles [1][2][3]. In recent years, the research on the treatment and prevention of HIV/AIDS remain a challenging endeavor for researchers.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, structure–activity relationship and molecular docking of cyclohexenone based analogous as potent non-nucleoside reverse-transcriptase inhibitors

Nazar

Abdullah

Badshah

et al. 2015

Journal of Molecular Structure

View full text Add to dashboard Cite

“…Current treatment options for such resistant infections are challenging, because of a few alternate drugs which are potent. Furthermore the second line of therapies is associated with modest potencies, toxicity, and lack of bioavailability [3, 4]. …”

Section: Introductionmentioning

confidence: 99%

Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective

Vadlapudi

Vadlapatla²,

Mitra³

2013

PRI

View full text Add to dashboard Cite

Herpes simplex virus (HSV) infections can be treated efficiently by the application of antiviral drugs. The herpes family of viruses is responsible for causing a wide variety of diseases in humans. The standard therapy for the management of such infections includes acyclovir (ACV) and penciclovir (PCV) with their respective prodrugs valaciclovir and famciclovir. Though effective, long term prophylaxis with the current drugs leads to development of drug-resistant viral isolates, particularly in immunocompromised patients. Moreover, some drugs are associated with dose-limiting toxicities which limit their further utility. Therefore, there is a need to develop new antiherpetic compounds with different mechanisms of action which will be safe and effective against emerging drug resistant viral isolates. Significant advances have been made towards the design and development of novel antiviral therapeutics during the last decade. As evident by their excellent antiviral activities, pharmaceutical companies are moving forward with several new compounds into various phases of clinical trials. This review provides an overview of structure and life cycle of HSV, progress in the development of new therapies, update on the advances in emerging therapeutics under clinical development and related recent patents for the treatment of Herpes simplex virus infections.

show abstract

Antiviral Drug Resistance: Mechanisms and Clinical Implications

Cited by 180 publications

References 197 publications

A Strategy for the Rapid Identification of Fungal Metabolites and the Discovery of the Antiviral Activity of Pyrenocine a and Harzianopyridone

Development of real-time RT-PCR for human metapneumovirus

The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy

Synthesis, structure–activity relationship and molecular docking of cyclohexenone based analogous as potent non-nucleoside reverse-transcriptase inhibitors

Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective

Contact Info

Product

Resources

About